Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Halina Baran, Marcelin Jan Pietryja, Carina Kronsteiner and Berthold Kepplinger
The present study evaluates the action of Jerusalem Balsam with respect to the biosynthetic machinery of Kynurenic Acid (KYNA) synthesis e.g. the activity of the enzyme synthesizing KYNA, Kynurenine Aminotransferase II (KAT II) in the rat liver homogenate. Subsequently we compared the action of Jerusalem Balsam on KAT II activity in the rat liver homogenate with the action of Cerebrolysin and D-cycloserine, known to inhibit rat liver KAT II activities. We found that Jerusalem Balsam blocked dose-dependently and significantly KAT II activity in the rat liver homogenate. The effect of Jerusalem Balsam on KAT II activity comparing to action of Cerebrolysin or D-cycloserine was strong and significant and the inhibition was seen up to 5 hrs of assay incubation time. Obtained data suggest that lowering of KYNA synthesis by Jerusalem Balsam is notable biochemical effect since it might influence KYNA levels. Increased KYNA levels, respectively KYNA synthesis has been reported in stroke patient, in patient with respiration and cardiovascular problem and in neuropsychiatric disorders. The possible therapeutic mechanism and advantage of the remedy Jerusalem Balsam, i.e., mixture of plants might be due to modulation of KYNA synthesis and improvement of biochemical processes in the periphery and likely in the CNS.